홈 › 만성 림프구성 백혈병 › 오리건
오리건의 만성 림프구성 백혈병 임상 시험
만성 림프구성 백혈병 관련 연구 17개가 오리건 내 여러 지역에서 참여자를 모집하고 있습니다.
오리건의 도시
공식 연구 텍스트(영어)
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06846671A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06943872Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT04269902A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277231A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Oregon Health and Science University ( Site 5425), Portland
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05947851Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06784167A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Portland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06564038Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- 외 8개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- 외 3개
피험자 모집 중3상
65세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT07321652Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Oncology Associates of Oregon, Eugene
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT07520006Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06533579A Long-term Extension Study of PCI-32765 (Ibrutinib)
- Willamette Valley Cancer Center, Eugene
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 7. 31. 업데이트됨 · NCT01804686A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Williamette Valley Cancer Institute & Research Center, Eugene
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 19. 업데이트됨 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 4. 9. 업데이트됨 · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 13. 업데이트됨 · NCT05544019Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- OHSU Knight Cancer Institute, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 11. 6. 업데이트됨 · NCT05943496A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 10. 2. 업데이트됨 · NCT05780034ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.